

Application No. 10/608,207
Supplemental Amendment

REMARKS/ARGUMENTS


Applicants representative would like to thank Examiner Desai for the discussion on February 11, 2005, and the indication of allowable subject matter in the present application upon making the above amendments.

Claims 1, 3-4 and 6-13, 15-18 and 20 are present in this application. Claims 2, 14 and 19 have been canceled by the present amendment. Claims 1 and 16 have been amended to remove the definition of "n" and to remove the listing of halogens in parentheses, as this listing was deemed redundant by the Examiner. Claims 6-11 have been amended to note that the R and S designations refer to the 20-position of the Camptothecin structure. These amendments are not further limiting of the claims, since there is no "n" remaining in the claimed compounds and the 20-position is the only chiral center located in the core structure. The claims to treatment of leukemia have been amended to recite a "therapeutically effective amount" of the compound. Claims 15 and 20 have been amended to remove Formula IV (drawn to non-elected subject matter) and to make the claims contain all limitations of the allowed product claims, thus being rejoinable. The amendments are supported by the original claims. No new matter has been added by these amendments.

The application is now believed to be in condition for allowance and early notification of such action is earnestly solicited.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.



J. Derek Mason, Ph.D.
Attorney of Record
Registration No. 35,270

Customer Number
22850

Tel: (703) 413-3000
Fax: (703) 413-2220
(OSMMN 06/04)